BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20220101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20231205
DTEND;VALUE=DATE:20231208
DTSTAMP:20260516T082616
CREATED:20230915T100043Z
LAST-MODIFIED:20230915T100043Z
UID:37804-1701734400-1701993599@www.pharmajournalist.com
SUMMARY:3rd ADC Target Selection Summit
DESCRIPTION:The 3rd ADC Target Selection Summit (December 5-7 | Boston\, MA). This is the ultimate cover-to-cover conference providing insights to help you optimize the pairing of target\, antibody\, and linker-payload and develop the next generation of clinically successful ADCs beyond HER2 and TROP2. \nSee the full program here. \nAs the number of new clinical ADC targets continues to increase\, this year’s meeting will have a greater focus on identifying and validating novel targets\, re-examining what makes a good target\, and delving into the use of proteomics to ensure you get the first step of drug development right. \nHere are some of the agenda highlights you cannot afford to miss: \n\nJoin Cancer Research Horizons to learn “Overcoming Hurdles in Validating Novel Targets for Clinically Applicable ADCs” and hear how an unbiased proteomics approach with patient samples was used to discover a clinically relevant ADC target for multiple myeloma\nHear from Ziel Bio on “Discovering Cell Surface Plectin: A Highly Promising Target for Multiple Solid Tumors” to understand how the hypothesized function of plectin highlights it as a good ADC target\, and learn how ZB131 can selectively bind to CSP improving internalization and minimizing off-target effects\nGain insights from AstraZeneca on “A Case Study on Utilizing Hindsight Following Progression of an ADC With a HER2 Target Into the Clinic” highlighting the target selection process and reasons behind the choice of pursuing HER2\, target and antibody considerations; and emphasizing challenges and successes in the use of this target for ADCs to help you prepare for your development.\n\nTake a look at the full speaker faculty and session details. \nUniting 100+ of your peers working in biology\, discovery and oncology research\, this unique forum will provide you with an exclusive opportunity to learn and network with other ADC developers who are living and breathing targets all in one room.
URL:https://www.pharmajournalist.com/event/3rd-adc-target-selection-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:adc@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20231205
DTEND;VALUE=DATE:20231208
DTSTAMP:20260516T082616
CREATED:20230920T102331Z
LAST-MODIFIED:20230920T102331Z
UID:37817-1701734400-1701993599@www.pharmajournalist.com
SUMMARY:3rd Applied Biocatalysis Summit
DESCRIPTION:Enzyme Engineering Enabling Scalable Industrial Biotransformation for Sustainable API Production \nIn 2023\, an era of advanced enzyme engineering technology is rapidly enabling the generation of game-changing enzymes for novel transformations. As witnessed for Merck’s Islatravir and BMS’ ERED/KRED biocatalytic cascade recognition\, industries are fast transitioning towards biocatalysis to capitalize on more sustainable means of synthesis. The 3rd Applied Biocatalysis Summit is your must-attend meeting dedicated to accelerating enzyme discovery and reaction route development\, through to scaling process chemistry for industrial applications. \nWith unmissable case studies from the likes of Merck\, Amgen\, Sanofi\, Biogen\, GSK\, and Pfizer\, this is the definitive forum to benchmark and learn with this forward-thinking community who reunite once more. \nThese industry titans have collaborated to form a comprehensive\, 3-day program covering key topics including: \n\nGaining valuable insights on chemoenzymatic catalysis research\, combining heterogeneous and homogeneous catalysis and making valued functionality using biocatalysis\, in water with Bruce Lipshutz\, Professor of Chemistry\, University of California\, Santa Barbara\nLearn how new technologies are adding efficiencies to biocatalysis’ adoption\, including AI/ML approaches\, improved screening for reaction prediction & new chemistry discoveries with Merck & Pfizer\nEngage in dynamic panel discussions addressing how cross-departmental collaboration enable the faster assessment and introduction of enzymatic catalysed reactions as early as possible with AbbVie\, Biogen & Neorocrine Biosciences\n\nDon’t miss this opportunity to join trailblazers and accelerate enzyme discovery and engineering\, discover carbon footprint-reducing reactions and refine your process scaling strategies.
URL:https://www.pharmajournalist.com/event/3rd-applied-biocatalysis-summit/
LOCATION:The Study at University City\, 20 S 33rd Street\, Philadelphia\, PA\, 19104\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR